Inflammatory Markers Response To Citrulline Supplementation In Patients With Non-alcoholic Fatty Liver Disease: A Randomized, Double Blind, Placebo-controlled, Clinical Trial
Notes for this study:
||Fibrosis. Mean and SD. kPa. Placebo: before 6.27 ± 2.08, after 6.12 ± 1.81. Citrulline: before 5.85 ± 1.71, after 5.84 ± 2.00.
|Number of Subjects
In this randomized, double-blind, placebo-controlled trial, 50 patients with NAFLD took 2 g of l-citrulline or placebo daily for 3 months.
83% of participants completed the study. There was a notably greater, statistically significant reduction in c-reactive protein and Nf-kb in the citrulline group compared with the placebo group, though there wasn't a notable difference for TNF-a. However, this didn't coincide with a notable difference in fibrosis or steatosis.